International audienceBackground: In Europe, there exists considerable variability in access ă to care and treatment for multiple sclerosis (MS). ă Objectives: To improve this situation, we identified key issues payers ă should take into account when making decisions on access to care and ă treatment for MS. We also give an overview of the different dimensions ă determining total MS burden and discuss why it is key to integrate the ă patient's perspective in estimating this burden. ă Results: The total burden of MS relates to three dimensions: clinical, ă humanistic and economic. Although the clinical burden is extensively ă studied, crucial information is still missing about MS pathophysiology, ă how MS-related symptoms will develop during...
Background: MS is a highly heterogeneous disease, both in its course and in its response to treatmen...
Background: Multiple sclerosis is a chronic and highly debilitating disease with very high economic ...
International audienceBackground: As multiple sclerosis (MS) is a chronic disease which starts at yo...
BACKGROUND: Patient engagement is vital in multiple sclerosis (MS) in order to optimise outcomes fo...
Mar Tintoré,1 Maggie Alexander,2 Kathleen Costello,3 Martin Duddy,4 David E Jones,5 Nancy Law...
Background Multiple sclerosis (MS) is the most common autoimmune inflammatory disease of the central...
Background: Multiple sclerosis (MS) has a major impact on the physical, psychological and social lif...
Introduction: Listening to patients’ voices is increasingly being recognized as an important factor ...
OBJECTIVES: This study aimed to capture the socio-economic costs, Health Related Quality of Life (HR...
BACKGROUND: In the past two decades the widespread use of disease modifying drugs with moderate to s...
Alberto Riñon1, Mandy Buch2, Derek Holley2, Elisabetta Verdun11Merck Serono S.A. &nda...
ultiple sclerosis (MS) is a chronic progressive disease of the CNS causing disability and neurologi...
International audienceINTRODUCTION: Evaluating the quality of the care pathway for patients with chr...
Multiple Sclerosis (MS) is the most common demyelinating disease of the Central Nervous System. It i...
Background: The current focus in multiple sclerosis (MS) is on early diagnosis and drug intervention...
Background: MS is a highly heterogeneous disease, both in its course and in its response to treatmen...
Background: Multiple sclerosis is a chronic and highly debilitating disease with very high economic ...
International audienceBackground: As multiple sclerosis (MS) is a chronic disease which starts at yo...
BACKGROUND: Patient engagement is vital in multiple sclerosis (MS) in order to optimise outcomes fo...
Mar Tintoré,1 Maggie Alexander,2 Kathleen Costello,3 Martin Duddy,4 David E Jones,5 Nancy Law...
Background Multiple sclerosis (MS) is the most common autoimmune inflammatory disease of the central...
Background: Multiple sclerosis (MS) has a major impact on the physical, psychological and social lif...
Introduction: Listening to patients’ voices is increasingly being recognized as an important factor ...
OBJECTIVES: This study aimed to capture the socio-economic costs, Health Related Quality of Life (HR...
BACKGROUND: In the past two decades the widespread use of disease modifying drugs with moderate to s...
Alberto Riñon1, Mandy Buch2, Derek Holley2, Elisabetta Verdun11Merck Serono S.A. &nda...
ultiple sclerosis (MS) is a chronic progressive disease of the CNS causing disability and neurologi...
International audienceINTRODUCTION: Evaluating the quality of the care pathway for patients with chr...
Multiple Sclerosis (MS) is the most common demyelinating disease of the Central Nervous System. It i...
Background: The current focus in multiple sclerosis (MS) is on early diagnosis and drug intervention...
Background: MS is a highly heterogeneous disease, both in its course and in its response to treatmen...
Background: Multiple sclerosis is a chronic and highly debilitating disease with very high economic ...
International audienceBackground: As multiple sclerosis (MS) is a chronic disease which starts at yo...